Zoe Brown, Dylan Hansen, Wendy Stevens, Nava Ferdowsi, Laura Ross, Alannah Quinlivan, Joanne Sahhar, Gene-Siew Ngian, Diane Apostolopoulos, Jennifer G Walker, Susanna Proudman, Gim Gee Teng, Andrea Hl Low, Kathleen Morrisroe, Mandana Nikpour
OBJECTIVE: Pulmonary arterial hypertension (PAH) patients may be stratified as low, intermediate, or high risk of 1-year mortality. In 2022, the European Society of Cardiology (ESC) updated and simplified its risk stratification tool, based on three variables: WHO functional class (FC), serum N-terminal pro-brain type natriuretic peptide (NT-proBNP) and six-minute walk distance (6MWD)), applied at follow up visits, intended to guide therapy over time. METHODS: We applied the 2022 ESC risk assessment tool at baseline and follow up (within two years) to a multinational incident cohort of systemic sclerosis-associated PAH (SSc-PAH)...
March 24, 2024: Arthritis Care & Research